{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5v1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10107","date":"2024-12-11T17:00:00.000Z","role":"Approver"},{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10107","date":"2024-12-12T00:41:48.784Z","role":"Publisher"}],"curationReasons":{"id":"cg:ErrorClarification"},"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/11704758","type":"dc:BibliographicResource","dc:abstract":"Leukoencephalopathy with vanishing white matter (VWM) is an inherited brain disease that occurs mainly in children. The course is chronic-progressive with additional episodes of rapid deterioration following febrile infection or minor head trauma. We have identified mutations in EIF2B5 and EIF2B2, encoding the epsilon- and beta-subunits of the translation initiation factor eIF2B and located on chromosomes 3q27 and 14q24, respectively, as causing VWM. We found 16 different mutations in EIF2B5 in 29 patients from 23 families. We also found two distantly related individuals who were homozygous with respect to a missense mutation in EIF2B2, affecting a conserved amino acid. Three other patients also had mutations in EIF2B2. As eIF2B has an essential role in the regulation of translation under different conditions, including stress, this may explain the rapid deterioration of people with VWM under stress. Mutant translation initiation factors have not previously been implicated in disease.","dc:creator":"Leegwater PA","dc:date":"2001","dc:title":"Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter."},"evidence":[{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4a9e678c-e482-44f4-94ef-3b9f214ba1ca_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4a9e678c-e482-44f4-94ef-3b9f214ba1ca","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":7,"allele":[{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.638A>G (p.Glu213Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA116769"}},{"id":"cggv:a7eaf701-2f54-4ef0-ad70-4da5c0c58323","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.818A>G (p.Lys273Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7275055"}}],"firstTestingMethod":"PCR","phenotypeFreeText":"motor signs potentially coupled with acute episode; cavitation present on brain MRI","phenotypes":"obo:HP_0002352","sex":"Male","variant":[{"id":"cggv:d6372995-f4be-467d-954e-06798bc0d782_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a7eaf701-2f54-4ef0-ad70-4da5c0c58323"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15136673","type":"dc:BibliographicResource","dc:abstract":"Recessive mutations in the five eucaryotic initiation factor 2B (eIF2B) subunits have been found in leukodystrophies of variable age at onset and severity.","dc:creator":"Fogli A","dc:date":"2004","dc:title":"The effect of genotype on the natural history of eIF2B-related leukodystrophies."}},{"id":"cggv:ac248e28-2013-4c0a-85fa-1da31b651a06_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"}],"rdfs:label":"Fogli 76-2"},{"id":"cggv:d6372995-f4be-467d-954e-06798bc0d782","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d6372995-f4be-467d-954e-06798bc0d782_variant_evidence_item"},{"id":"cggv:d6372995-f4be-467d-954e-06798bc0d782_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Percent GEF eIF2B activity decreased compared to controls (Fogli et al. 2004)."}],"strengthScore":0.5},{"id":"cggv:ac248e28-2013-4c0a-85fa-1da31b651a06","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ac248e28-2013-4c0a-85fa-1da31b651a06_variant_evidence_item"},{"id":"cggv:ac248e28-2013-4c0a-85fa-1da31b651a06_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Percent GEF eIF2B activity decreased compared to controls (Fogli et al. 2004)."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:bd2f823a-5f03-4622-bb94-852bd978ad40_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:bd2f823a-5f03-4622-bb94-852bd978ad40","type":"Proband","allele":[{"id":"cggv:d28a9c5b-72c9-4c11-9f38-5a060c780e0e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.548del (p.Arg183GlnfsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7274971"}},{"id":"cggv:a7eaf701-2f54-4ef0-ad70-4da5c0c58323"}],"firstTestingMethod":"PCR","phenotypeFreeText":"Individual part of originally published cohort with confirmed clinical data and/or imaging.","sex":"UnknownEthnicity","variant":[{"id":"cggv:ede1a67e-4509-4228-a8ca-d8d3de838a64_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d28a9c5b-72c9-4c11-9f38-5a060c780e0e"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/11704758"},{"id":"cggv:ade708ec-289f-4f6a-9e03-ecbb8584f486_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a7eaf701-2f54-4ef0-ad70-4da5c0c58323"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/11704758"}],"rdfs:label":"Leegwater vwm235"},{"id":"cggv:ede1a67e-4509-4228-a8ca-d8d3de838a64","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:ede1a67e-4509-4228-a8ca-d8d3de838a64_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:ade708ec-289f-4f6a-9e03-ecbb8584f486","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ade708ec-289f-4f6a-9e03-ecbb8584f486_variant_evidence_item"},{"id":"cggv:ade708ec-289f-4f6a-9e03-ecbb8584f486_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Cells from VWMD patient (study label: VWMD-2) hypersuppress translation during acute stress (Moon & Parker 2018)"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ff7a9376-c259-4aa1-88bc-3602527e2a2d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ff7a9376-c259-4aa1-88bc-3602527e2a2d","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":8,"allele":[{"id":"cggv:42722500-d2f3-414a-b07a-5d3bdd9f293c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.682A>G (p.Arg228Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7275018"}},{"id":"cggv:10faed8a-629c-48dd-8e13-81c8ace0ad67","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.254T>A (p.Val85Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343824"}}],"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"spasticity; developmental delay; provoked by fever","phenotypes":["obo:HP_0012758","obo:HP_0002352","obo:HP_0001257"],"sex":"Male","variant":[{"id":"cggv:1e1dd7c9-3931-46c1-a0eb-813e4015a8d2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:42722500-d2f3-414a-b07a-5d3bdd9f293c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25843247","type":"dc:BibliographicResource","dc:abstract":"Vanishing white matter disease (VWM) is a chronic, progressive leukoencephalopathy associated with episodes of rapid deterioration following minor stress events such as head traumas or infectious disorders. The white matter of the patients with VWM exhibits characteristic radiological findings.","dc:creator":"Shimada S","dc:date":"2015","dc:title":"Mutations in the genes encoding eukaryotic translation initiation factor 2B in Japanese patients with vanishing white matter disease."}},{"id":"cggv:b2057493-3056-4a08-948a-dbfe4167cd71_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:10faed8a-629c-48dd-8e13-81c8ace0ad67"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25843247"}],"rdfs:label":"Shimada Patient 3"},{"id":"cggv:1e1dd7c9-3931-46c1-a0eb-813e4015a8d2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:1e1dd7c9-3931-46c1-a0eb-813e4015a8d2_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:b2057493-3056-4a08-948a-dbfe4167cd71","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:b2057493-3056-4a08-948a-dbfe4167cd71_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c416fb64-59c5-42c9-ad60-578ceccee1bd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c416fb64-59c5-42c9-ad60-578ceccee1bd","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":8,"allele":[{"id":"cggv:72359676-6dfe-41a3-97e4-63c36c9b1d7a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.547C>T (p.Arg183Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA116770"}},{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"}],"firstTestingMethod":"PCR","phenotypeFreeText":"school difficulties; motor signs; localized cavitation on brain MRI","phenotypes":["obo:HP_0002352","obo:HP_0001249"],"sex":"Female","variant":[{"id":"cggv:2c487400-fe0e-49e9-89d0-966aa817d2a2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:72359676-6dfe-41a3-97e4-63c36c9b1d7a"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"},{"id":"cggv:491a2685-e7c2-4f5b-b134-fcdc2f7c5e24_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"}],"rdfs:label":"Fogli 992"},{"id":"cggv:2c487400-fe0e-49e9-89d0-966aa817d2a2","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:2c487400-fe0e-49e9-89d0-966aa817d2a2_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:491a2685-e7c2-4f5b-b134-fcdc2f7c5e24","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:491a2685-e7c2-4f5b-b134-fcdc2f7c5e24_variant_evidence_item"},{"id":"cggv:491a2685-e7c2-4f5b-b134-fcdc2f7c5e24_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Cells from VWMD patient (study label: VWMD-2) hypersuppress translation during acute stress (Moon & Parker 2018)"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:55c726af-0858-4108-8594-f66283da5617_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:55c726af-0858-4108-8594-f66283da5617","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":41,"allele":[{"id":"cggv:10faed8a-629c-48dd-8e13-81c8ace0ad67"},{"id":"cggv:bb3994ae-2caf-4d54-abf9-5accd4383d10","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.268C>T (p.Arg90Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA390424130"}}],"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"leukoencephalopathy on MRI; headaches","phenotypes":["obo:HP_0002059","obo:HP_0032325","obo:HP_0007371","obo:HP_0002352","obo:HP_0002315"],"sex":"Male","variant":[{"id":"cggv:61ef6651-3893-4a7e-9932-c17434ebd76e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:10faed8a-629c-48dd-8e13-81c8ace0ad67"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29700822","type":"dc:BibliographicResource","dc:abstract":"Leukoencephalopathies encompass all clinical syndromes that predominantly affect brain white matter. Genetic diagnosis informs clinical management of these patients, but a large part of the genetic contribution to adult leukoencephalopathy remains unresolved. To examine this genetic contribution, we analyzed genomic DNA from 60 Japanese patients with adult leukoencephalopathy of unknown cause by next generation sequencing using a custom-designed gene panel. We selected 55 leukoencephalopathy-related genes for the gene panel. We identified pathogenic mutations in 8 of the 60 adult leukoencephalopathy patients (13.3%): NOTCH3 mutations were detected in 5 patients, and EIF2B2, CSF1R, and POLR3A mutations were found independently in 1 patient each. These results indicate that cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) caused by NOTCH3 mutations is the most frequent adult leukoencephalopathy in our cohort. Moreover, brain imaging analysis indicates that CADASIL patients who do not present typical phenotypes may be underdiagnosed if not examined genetically.","dc:creator":"Kunii M","dc:date":"2018","dc:title":"Genetic analysis of adult leukoencephalopathy patients using a custom-designed gene panel."}},{"id":"cggv:5b10460c-5546-497b-a960-b26a8e6a0c24_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:bb3994ae-2caf-4d54-abf9-5accd4383d10"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29700822"}],"rdfs:label":"Kuni 40"},{"id":"cggv:5b10460c-5546-497b-a960-b26a8e6a0c24","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:5b10460c-5546-497b-a960-b26a8e6a0c24_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:61ef6651-3893-4a7e-9932-c17434ebd76e","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:61ef6651-3893-4a7e-9932-c17434ebd76e_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8e03c6d4-5f4e-4a40-bdd9-7db613ff1596_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8e03c6d4-5f4e-4a40-bdd9-7db613ff1596","type":"Proband","allele":{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},"phenotypeFreeText":"Individual part of originally published cohort with confirmed clinical data and/or imaging.","sex":"UnknownEthnicity","variant":{"id":"cggv:45b0dac7-1565-4eb9-abfe-4b5661a6701a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/11704758"},"rdfs:label":"Leegwater vwm63"},{"id":"cggv:45b0dac7-1565-4eb9-abfe-4b5661a6701a","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:45b0dac7-1565-4eb9-abfe-4b5661a6701a_variant_evidence_item"},{"id":"cggv:45b0dac7-1565-4eb9-abfe-4b5661a6701a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Cells from VWMD patient (study label: VWMD-2) hypersuppress translation during acute stress (Moon & Parker 2018)"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":11.2},{"id":"cggv:665d40d7-0f3f-4d26-bb6a-e3c70a82526d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:665d40d7-0f3f-4d26-bb6a-e3c70a82526d","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},{"id":"cggv:5c9bd9ab-58ec-4ef9-a480-53ce3c5d0deb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.599G>C (p.Gly200Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA263654958"}}],"firstTestingMethod":"PCR","phenotypeFreeText":"delay in motor development in the first 2 years of age; speech delay; motor signs potentially coupled with acute episode; relapsing remitting disease; cavitation present on brain MRI","phenotypes":["obo:HP_0002352","obo:HP_0000750","obo:HP_0001270"],"sex":"Male","variant":[{"id":"cggv:162c1842-c3a7-4705-96eb-eeaad7b3bd00_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"},{"id":"cggv:e85f7575-eff3-4554-b365-deffa616acf2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5c9bd9ab-58ec-4ef9-a480-53ce3c5d0deb"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"}],"rdfs:label":"Fogli 328"},{"id":"cggv:162c1842-c3a7-4705-96eb-eeaad7b3bd00","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:162c1842-c3a7-4705-96eb-eeaad7b3bd00_variant_evidence_item"},{"id":"cggv:162c1842-c3a7-4705-96eb-eeaad7b3bd00_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Cells from VWMD patient (study label: VWMD-2) hypersuppress translation during acute stress (Moon & Parker 2018)."}],"strengthScore":0.5},{"id":"cggv:e85f7575-eff3-4554-b365-deffa616acf2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:e85f7575-eff3-4554-b365-deffa616acf2_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a0f12570-7fba-47d3-9d2a-6172a3acde79_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a0f12570-7fba-47d3-9d2a-6172a3acde79","type":"Proband","allele":[{"id":"cggv:91528b19-79d8-464b-af99-97006585dac2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.607_612delinsTG (p.Met203TrpfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA116773"}},{"id":"cggv:d186d587-48ab-4a2d-9e99-36dd8adae475","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.986G>T (p.Gly329Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA263656912"}}],"firstTestingMethod":"PCR","phenotypeFreeText":"Individual part of originally published cohort with confirmed clinical data and/or imaging.","sex":"UnknownEthnicity","variant":[{"id":"cggv:646c167f-8db9-4945-8f66-4c86633ce89d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:91528b19-79d8-464b-af99-97006585dac2"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/11704758"},{"id":"cggv:c552700b-0057-48c1-8a3d-bbf931e641c1_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d186d587-48ab-4a2d-9e99-36dd8adae475"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/11704758"}],"rdfs:label":"Leegwater vwm83"},{"id":"cggv:646c167f-8db9-4945-8f66-4c86633ce89d","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:646c167f-8db9-4945-8f66-4c86633ce89d_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:c552700b-0057-48c1-8a3d-bbf931e641c1","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c552700b-0057-48c1-8a3d-bbf931e641c1_variant_evidence_item"},{"id":"cggv:c552700b-0057-48c1-8a3d-bbf931e641c1_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Percent GEF eIF2B activity decreased by <50% (Liu 2011)."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:57ed9e3d-a6a9-4570-bb68-067303b41d0f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:57ed9e3d-a6a9-4570-bb68-067303b41d0f","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":18,"allele":[{"id":"cggv:7572c1dc-4235-43bf-9efc-e457392a9b7d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.910G>T (p.Glu304Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA263656848"}},{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"}],"firstTestingMethod":"PCR","phenotypeFreeText":"Relapsing remitting disease; brain MRI demonstrates cavitation","phenotypes":"obo:HP_0002352","sex":"Male","variant":[{"id":"cggv:88a7262f-f3d1-41e9-871a-55e387150e99_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d0d41f63-b15b-446a-9f12-674d67c10cc1"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"},{"id":"cggv:88d856db-bc6f-4793-9871-cd4f19dae597_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7572c1dc-4235-43bf-9efc-e457392a9b7d"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673"}],"rdfs:label":"Fogli 433-2"},{"id":"cggv:88a7262f-f3d1-41e9-871a-55e387150e99","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:88a7262f-f3d1-41e9-871a-55e387150e99_variant_evidence_item"},{"id":"cggv:88a7262f-f3d1-41e9-871a-55e387150e99_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Cells from VWMD patient (study label: VWMD-2) hypersuppress translation during acute stress (Moon & Parker 2018)"}],"strengthScore":0.5},{"id":"cggv:88d856db-bc6f-4793-9871-cd4f19dae597","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:88d856db-bc6f-4793-9871-cd4f19dae597_variant_evidence_item"},{"id":"cggv:88d856db-bc6f-4793-9871-cd4f19dae597_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Cells from VWMD patient (study label: VWMD-2) hypersuppress translation during acute stress (Moon & Parker 2018)"}],"strengthScore":1.5,"dc:description":"Per ClinGen NDWG scoring guidelines proband scores are capped at 2"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:aa393c8b-66d2-4a5f-8ff9-f049cd4dccba_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:aa393c8b-66d2-4a5f-8ff9-f049cd4dccba","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"allele":[{"id":"cggv:a3685b71-95dd-4f39-afef-f4428105f4a6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014239.4(EIF2B2):c.496A>G (p.Met166Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA390425868"}},{"id":"cggv:10faed8a-629c-48dd-8e13-81c8ace0ad67"}],"firstTestingMethod":"PCR","phenotypeFreeText":"menometrorrhagia; tremors; bilateral pyramidal tract injury; cerebellar ataxia; dementia; white matter abnormalities on brain MRI","phenotypes":["obo:HP_0002352","obo:HP_0001251","obo:HP_0400008"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:5cb5a6e2-96ec-4ddb-82eb-f0b9e7005c8a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a3685b71-95dd-4f39-afef-f4428105f4a6"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31438897","type":"dc:BibliographicResource","dc:abstract":"Vanishing white matter disease (VWMD) is one of the most prevalent inherited leukoencephalopathies, which generally presents in childhood as a progressive disorder while less beginning in adulthood. The present report describes the clinical, neuroimaging, and genetic findings of a female patient with adult-onset VWMD. In addition, to provide a clearer delineation of the clinical and genetic characteristics of female adult-onset VWMD patients, 32 genetically confirmed female adult-onset EIF2B-mutated cases are summarized.","dc:creator":"Wei C","dc:date":"2019","dc:title":"Adult-onset vanishing white matter disease with the EIF2B2 gene mutation presenting as menometrorrhagia."}},{"id":"cggv:b68f5de7-e47a-4d89-8fb7-9d8735b5ae96_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:10faed8a-629c-48dd-8e13-81c8ace0ad67"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31438897"}],"rdfs:label":"Wei"},{"id":"cggv:5cb5a6e2-96ec-4ddb-82eb-f0b9e7005c8a","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:5cb5a6e2-96ec-4ddb-82eb-f0b9e7005c8a_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:b68f5de7-e47a-4d89-8fb7-9d8735b5ae96","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:b68f5de7-e47a-4d89-8fb7-9d8735b5ae96_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11.2},{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:8a7b5a82-55e8-4bfd-bfb9-be0dbe67c78d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:68be391d-2000-49c1-9360-6817accc83b5","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"eIF2B is a decameric, a dimer of eIF2B (beta, gamma, delta, epsilon) tetramers stabilized by 2 copies of eIF2B. EIF2B2 is experimentally proven to interact with EIF2B5, which has been established to cause EIF2B related disorder. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24532666","type":"dc:BibliographicResource","dc:abstract":"Eukaryotic initiation factor 2B (eIF2B) is the guanine nucleotide exchange factor for eIF2 and a critical regulator of protein synthesis, (e.g., as part of the integrated stress response). Certain mutations in the EIF2B genes cause leukoencephalopathy with vanishing white matter (VWM), an often serious neurological disorder. Comprising 5 subunits, α-ε (eIF2Bε being the catalytic one), eIF2B has always been considered an αβγδε heteropentamer. We have analyzed the subunit interactions within mammalian eIF2B by using a combination of mass spectrometry and in vivo studies of overexpressed complexes to gain further insight into the subunit arrangement of the complex. Our data reveal that eIF2B is actually decameric, a dimer of eIF2B(βγδε) tetramers stabilized by 2 copies of eIF2Bα. We also demonstrate a pivotal role for eIF2Bδ in the formation of eIF2B(βγδε) tetramers. eIF2B(αβγδε)2 decamers show greater binding to eIF2 than to eIF2B(βγδε) tetramers, which may underlie the increased activity of the former. We examined the levels of eIF2B subunits in a panel of different mouse tissues and identified different levels of eIF2B subunits, particularly eIF2Bα, which implies heterogeneity in the cellular proportions of eIF2B(αβγδε) and eIF2B(βγδε) complexes, with important implications for the regulation of translation in individual cell types.","dc:creator":"Wortham NC","dc:date":"2014","dc:title":"Analysis of the subunit organization of the eIF2B complex reveals new insights into its structure and regulation."},"rdfs:label":"Protein Interaction"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:1e75d5fe-a4d4-418d-91f6-d731aa196414","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:27668782-cd73-44db-b30e-ccbc5c121871","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Model recapitulates motor impairment and abnormal CNS development seen in patients with VWM. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33300869","type":"dc:BibliographicResource","dc:abstract":"Vanishing white matter disease (VWM) is a severe leukodystrophy of the central nervous system caused by mutations in subunits of the eukaryotic initiation factor 2B complex (eIF2B). Current models only partially recapitulate key disease features, and pathophysiology is poorly understood. Through development and validation of zebrafish (","dc:creator":"Keefe MD","dc:date":"2020","dc:title":"Vanishing white matter disease expression of truncated EIF2B5 activates induced stress response."},"rdfs:label":"Zebrafish"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Non-mammalian model"}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Definitive","sequence":9505,"specifiedBy":"GeneValidityCriteria11","strengthScore":12.7,"subject":{"id":"cggv:b22e0383-b970-49e3-ab75-7c2ee9443473","type":"GeneValidityProposition","disease":"obo:MONDO_0957870","gene":"hgnc:3258","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","dc:description":"EIF2B2 was first associated with autosomal recessive leukoencephalopathy with vanishing white matter in 2001 (Leegwater., PMID: 11704758). Individuals with EIF2B2-related leukoencephalopathy present with gait dysfunction, spasticity, cognitive decline, and white matter abnormalities on MRI.  Some individuals develop ovarian failure. Onset is variable from infancy to adulthood, and progression of disease is often in the setting of fever, trauma, or stress. Vanishing white matter disease has also been referred to as Childhood Ataxia with Central Nervous System Hypomyelination (CACH). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found that a phenotypic spectrum exists and there is no difference in molecular mechanism or inheritance pattern. Therefore, we chose to curate this gene-disease relationship under the disease term leukoencephalopathy with vanishing white matter 2 (OMIM:606454, MONDO:0957870). \n\nTwelve variants (missense, nonsense, frameshift) that have been reported in 10 probands in 5 publications (PMIDs: 15136673, 29700822, 11704758, 25843247, 31438897) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is reported to be loss of function. This gene-disease relationship is also supported by experimental evidence, (PMIDs: 33300869, 24532666). The zebrafish model is associated with impaired motor behavior and abnormal CNS development. Protein interaction studies have shown that the subunit encoded by EIF2B2 interacts with the subunit of a previously curated gene EIF2B5.   In summary, definitive evidence supports the relationship between EIF2B2 and autosomal recessive leukoencephalopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Leukodystrophy and Leukoencephalopathy GCEP on the meeting date October 16, 2024 (SOP Version 11).\n","dc:isVersionOf":{"id":"cggv:875faedd-30bd-4e6d-803f-6244a04f37a5"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}